共 50 条
- [41] Rapid response to fifth-line brigatinib plus entrectinib in an ALK-rearranged lung adenocarcinoma with an acquired ETV6-NTRK3 fusion: a case report [J]. FRONTIERS IN ONCOLOGY, 2024, 14
- [42] Crizotinib rechallenge reverses MET amplification-mediated resistance to ALK inhibitors in a patient with advanced ALK-rearranged non-small cell lung cancer: a case report [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2020, 13 (08): : 6163 - 6167
- [44] Remarkable Clinical Response of ALK-Rearranged/ TP53-Mutant Lung Adenocarcinoma with Liver Metastasis to Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel After ALK Inhibitors: A Case Report [J]. ONCOTARGETS AND THERAPY, 2023, 16 : 465 - 470
- [47] Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib [J]. FRONTIERS IN ONCOLOGY, 2021, 11